Literature DB >> 2419814

Proliferative sickle retinopathy and neovascularization of the disc: regression following treatment with peripheral retinal scatter laser photocoagulation.

A S Kimmel, L E Magargal, W S Tasman.   

Abstract

Proliferative sickle retinopathy (PSR) is usually described as a peripheral neovascular tuft in a "sea fan" like configuration. While neovascularization of the disc (NVD) is a common finding in proliferative diabetic retinopathy (PDR), to our knowledge only one other case has been reported of NVD in an S-C patient in the absence of other contributing conditions. PSR has been shown to regress after treating hypoxic peripheral retina with peripheral circumferential retinal scatter photocoagulation (PCRSP). The following is a case report of an S-C patient with PSR and NVD/NVR which was originally treated elsewhere with scatter argon laser photocoagulation from the vascular arcades to just behind the equator. The peripheral "sea fan" and NVD did not regress. PCRSP to the zone of peripheral ischemia was then performed, and regression of the NVD and peripheral "sea fan" was achieved. This case illustrates the importance of concentrating laser treatment to the zones of retinal ischemia to achieve regression of associated neovascularization.

Entities:  

Mesh:

Year:  1986        PMID: 2419814

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  3 in total

1.  Relationship between peripheral vascular closure and proliferative retinopathy in sickle cell disease.

Authors:  J C van Meurs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

2.  Vitreoretinal management and surgical outcomes in proliferative sickle retinopathy: a case series.

Authors:  Royce W S Chen; Harry W Flynn; Wen-Hsiang Lee; D Wilkin Parke; Ryan F Isom; Janet L Davis; William E Smiddy
Journal:  Am J Ophthalmol       Date:  2013-12-31       Impact factor: 5.258

3.  Ocular findings in sickle cell patients on Curaçao.

Authors:  J C van Meurs
Journal:  Int Ophthalmol       Date:  1991-01       Impact factor: 2.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.